Tarsus to Participate at Upcoming Virtual Investor Conferences
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) has announced its participation in two upcoming virtual investor conferences to discuss advancements in eye care and other therapeutic categories.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) has announced its participation in two upcoming virtual investor conferences to discuss advancements in eye care and other therapeutic categories. The events are Ophthalmology Day at BTIG on November 30, 2021, and the Piper Sandler 33rd Annual Virtual Healthcare Conference on December 1-2, 2021. Tarsus is developing innovative treatments, including TP-03 for Demodex blepharitis in a Phase 3 trial and TP-05 for Lyme disease prevention in a Phase 1 trial. For updates, visit tarsusrx.com.
Details
News Market Reaction – TARS
The recorded move for TARS in the trading session of this news was +1.84%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
IRVINE, Calif., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that management will participate in the following virtual investor conferences:
- Ophthalmology Day at BTIG on Tuesday, November 30, 2021
- Piper Sandler 33rd Annual Virtual Healthcare Conference on December 1-2, 2021
The above listed dates are subject to change. Please check www.tarsusrx.com for the latest information.
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. It is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. The company is studying two investigational medicines in clinical trials. Its lead product candidate, TP-03, is a novel therapeutic being studied in a second Phase 3 pivotal trial for the treatment of Demodex blepharitis. TP-03 is also being developed for the treatment of Meibomian Gland Disease. Tarsus is developing TP-05, an oral, non-vaccine therapeutic for the prevention of Lyme disease, which is currently being studied in a Phase 1 clinical trial.
Contacts:
Media Contact:
SuJin Oh
Shop PR
(917) 841-5213
sujin@shop-pr.com
Investor Contact:
David Nakasone
Head of Investor Relations
(949) 620-3223
DNakasone@tarsusrx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.